The PRESERVE-001 study has shown efficacy from ONC-392, a new anti-CTLA-4 antibody, as a monotherapy in patients with non–small cell lung cancer and ovarian cancer.
Jonah Feldman
Advertisement
Jonah Feldman is an assistant editor for Targeted Oncology and Peers and Perspectives in Oncology.
Articles by Jonah Feldman
Arturo Loaiza-Bonilla, MD, MSEd, FACP, discussed recent trials and advances in neuroendocrine cancer research in an interview with Targeted Oncology for World Neuroendocrine Cancer Day.
A recently published study has shown no difference in survival outcomes for patients under 50 with colorectal cancer, despite greater treatment intensity and physical fitness.
In an interview with Targeted Oncology, Solange Peters, MD, discussed the significance of the 3-year follow-up analysis of the CheckMate 743 study of nivolumab/ipilimumab in mesothelioma.
Neeraj Agarwal, MD, spoke with Targeted Oncology about the success of the TITAN and SPARTAN studies as well as its use in real-world prostate cancer populations.
In an interview with Targeted Oncology, Erika Hamilton, MD, discussed the findings from a study of rebastinib plus paclitaxel and unmet needs in the ovarian cancer setting.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC
2
Dr Shubham Pant Highlights Progress and Promise in Pancreatic Cancer Treatment
3
FDA Accepts NDA of Zanzalintinib Combo for Pretreated Metastatic CRC
4
New Phase 2 Study of Tri-Modal Immunotherapy for Indolent B-Cell Lymphoma Launches
5